Author

A. Tedeschi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

A. Alhendi· 1 shared A. Amer· 1 shared A. Badr· 1 shared A. Dos Santos Dias· 1 shared A. Eddy· 1 shared A. Forero· 1 shared A. Kenney· 1 shared A. Khabbush· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Alhendi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Prenatal VEGF Nano-Delivery Reverses Congenital Diaphragmatic Hernia-Associated Pulmonary Abnormalities

S. Loukogeorgakis, F. Michielin, S. Shibuya, N. Al-Juffali, J. Jimenez, J. Allen-Hyttinen, P. Eastwood, A. Alhendi, J. Davidson, E. Naldi, P. Maghsoudlou, A. Tedeschi, S. Khalaf, A. Khabbush, M. Plate, , P. De Coppi

This paper investigates VEGF supplementation as a treatment for congenital diaphragmatic hernia (CDH)-associated lung abnormalities using an ex vivo model and nanoparticle-based delivery in vivo.

bioRxiv · Feb 20, 2024Bioengineering

Caspase-4/11 exacerbates disease severity in SARS-CoV-2 infection by promoting inflammation and thrombosis

M. Eltobgy, A. Zani, A. Kenney, S. Estfanous, E. Kim, A. Badr, C. Carafice, K. Daily, O. Whitham, M. Pietrzak, A. Webb, J. Kawahara, A. Eddy, P. Denz, M. Lu, , A. Amer

This study shows that caspase-4/11 worsens SARS-CoV-2 infection by increasing inflammation and thrombosis, independent of GSDMD, suggesting it as a potential drug target for severe COVID-19.

bioRxiv · Sep 24, 2021Immunology